ReviewBest practice & research. Clinical endocrinology & metabolism2023
Pituitary and SARS CoV-2: An unremitting conundrum.
Review in Best practice & research. Clinical endocrinology & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Hypophysitis in COVID-19: a systematic review.Pituitary · 2024Pooled it
- Pooled it
- Arginine vasopressin deficiency following SARS-CoV-2 infection: a rare pituitary complication.Endocrinology, diabetes & metabolism case reports · 2026Article
- Interplay Between Infectious Diseases and the Endocrine System: An Overview and Clinical Insights.Endocrinology, diabetes & metabolism · 2026Review
- Characterization of subchronic lung and brain consequences caused by mouse-adapted SARS-CoV-2 and influenza A infection of C57BL6 mice.Frontiers in immunology · 2026Article
- Persistent Changes in Hormones and Growth Factors Involved in Ageing in Patients That Recovered from Severe COVID-19.Diseases (Basel, Switzerland) · 2025Article
- Endocrine Disorders and COVID-19 Severity in Pediatric Populations: A Systematic Review.Cureus · 2025Review
- Growth hormone - releasing hormone in the immune system.Reviews in endocrine & metabolic disorders · 2025Review
- Arginine-vasopressin deficiency due to long COVID-associated infundibulo-neurohypophysitis.Archives of endocrinology and metabolism · 2025Article
- Central Hypothyroidism with Low TSH Compared to Normal TSH Is Associated with More Advanced Pituitary Disease and Less Favorable Metabolic Profile.Metabolites · 2025Article
- An overview of hypopituitarism's causes.Frontiers in endocrinology · 2025Review
- Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19.International journal of medical sciences · 2025Review
- Treatment and outcome of a boy with lgG4-related hypophysitis caused by SARS-CoV-2 re-infection.Frontiers in endocrinology · 2025Article
- Viral infection and thyroid disorders: a narrative review.Frontiers in microbiology · 2025Review
- Acromegaly and COVID-19, lessons, and new opportunities.Pituitary · 2024Article
- Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement.International journal of molecular sciences · 2024Review
- Thyroid dysfunction in COVID-19.Nature reviews. Endocrinology · 2024Review
- Response to Letter to the Editor From Josef Finsterer: "Explaining Long COVID: A Pioneer Cross-Sectional Study Supporting the Endocrine Hypothesis".Journal of the Endocrine Society · 2024Article
- The Growing Understanding of the Pituitary Implication in the Pathogenesis of Long COVID-19 Syndrome: A Narrative Review.Advances in respiratory medicine · 2024Review
- Explaining Long COVID: A Pioneer Cross-Sectional Study Supporting the Endocrine Hypothesis.Journal of the Endocrine Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increased interest related to the impact of coronavirus disease 19 (COVID-19) on the endocrine system and in particular on the pituitary gland. Over the course of the severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are both acute and delayed effects on the pituitary, related to infection and/or treatment. Hypopituitarism, pituitary apoplexy and hypophysitis have been all reported, as well as arginine vasopressin deficiency (diabetes insipidus) and syndrome of inappropriate antidiuretic hormone secretion. Furthermore, patients with acromegaly, Cushing's disease and hypopituitarism are theoretically at increased risk of complications with COVID-19 and require close monitoring. Evidence regarding pituitary dysfunction in patients with COVID-19 continues to be gathered, as the breadth and depth of knowledge also continues to rapidly evolve. This review summarizes data analysis to date on the possible effects of COVID-19 and COVID-19 vaccination on patients with normal pituitary function and patients with known pituitary pathology. Though clinical systems were significantly affected, it seems there is no overall loss of biochemical control in patients with certain pituitary pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.